Ann: 2022 Annual Report, page-3

Reading the details on Blumio & inHealth situation in the annual report. Paraphrasing so forgive me.
This reads like some serious cleaning up of the balance sheet before US listing ?

Blumio - we have written off the convertible note of USD $600k ie, valued at $0 now. Essentially, reviewed the financials provided by Blumio for the last 3 financial years and they are a basket case ... liabilities increasing and no sales other than grants. Management have deemed low likelihood on getting money repaid, so written off completely. Unfortunate.

InHealth - We have had an independent party value inHealth , which in turn has been signed off by the auditor ( but gets a special mention in the final signoff ... a bit of a warning shot for investors ). Our investment here was far more hefty than Blumio, $3M USD back in 2019. Since then, $500M USD has been repaid and interest owed by inHealth to CardieX over the ensuing period paid via issuance of equity to CardieX in InHealth.
We now own 8.35% of InHealth, and the convertible note maturity date has been extended to November 2023.
The 8.35% share has been valued at $648,000 USD, and the convertible note at AUD $5.43M.

So, InHealth still seems to have legs, and is part of the CONNEQT ecosystem ( a win/win for CardieX ).
Blumio, not so sure, a speculative play that the sensor technology may deliver one day ... at best.